Novartis Brings “Disruptive Innovation” To Clinical Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Having reinvigorated its model for early R&D, the company is looking to re-envision the clinical trial process, with initiatives aimed at improving patient selection based on molecular information, clinical trial recruitment and monitoring. A partnership with Walgreens aims to move trials out of tertiary care centers and into pharmacies.
You may also be interested in...
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
With more than 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.
Evolution, Not Revolution, Marks Progress In Targeted Oncology Therapy – AACR
The American Association for Cancer Research’s second annual Cancer Progress Report makes the case that oncology progression is more a process of refinement than breakthrough right now.
NIBR Model Improves Novartis Early Pipeline Success Rate
Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.